Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Observational Study in Late-Stage Elderly Patients with Non-Valvular Atrial FibrillationAll Nippon AF In Elderly Registry -ANAFIE Registry

Next Previous
Trial Profile

Prospective Observational Study in Late-Stage Elderly Patients with Non-Valvular Atrial FibrillationAll Nippon AF In Elderly Registry -ANAFIE Registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Embolism; Ischaemic stroke
  • Focus Therapeutic Use
  • Acronyms ANAFIE registry

Most Recent Events

  • 29 Aug 2022 Results of substudy (n=1474) assessing relations between echocardiographic parameters of left atrial structure and function and clinical outcomes at 2 years presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
  • 20 Apr 2022 Results assessing impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation, published in the Stroke
  • 30 Nov 2021 Results of a sub-analysis compared the incidence rates of clinical outcomes between active cancer and non-cancer groups published in the Circulation Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top